Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
148actual
Sites
137
Countries
Argentina, Australia, Brazil +22
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-10-28 | actual | When the study began enrolling |
| Primary completion | 2025-12-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-01 | estimated | The whole study's end, after follow-up |
| First posted | 2021-09-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Papillary Renal Cell Carcinoma
Interventions
- Drug: savolitinib — also filed as AZD6094, HMPL-504, volitinib
- Drug: durvalumab — also filed as MEDI4736
- Drug: sunitinib — also filed as Sutent, SU11248
Primary outcome
what the primary-completion date above is the date OFProgression-Free Survival (PFS) /savolitinib plus durvalumab relative to sunitinib
measured Approximately 28 months post first subject randomized
Publications
- PMID 41861260 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed